Gyre Therapeutics Net Worth
Gyre Therapeutics Net Worth Breakdown | GYRE |
Gyre Therapeutics Net Worth Analysis
Gyre Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Gyre Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Gyre Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Gyre Therapeutics' net worth analysis. One common approach is to calculate Gyre Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Gyre Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Gyre Therapeutics' net worth. This approach calculates the present value of Gyre Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Gyre Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Gyre Therapeutics' net worth. This involves comparing Gyre Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Gyre Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Gyre Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Gyre Therapeutics' net worth research are outlined below:
| Gyre Therapeutics generated a negative expected return over the last 90 days | |
| Gyre Therapeutics has high historical volatility and very poor performance | |
| Gyre Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 113.45 M. Net Loss for the year was (85.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| About 75.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Xenetic Biosciences, Inc. Releases Virtual Investor What This Means Segment |
Gyre Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Gyre Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gyre Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Gyre Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 968.93 M.Market Cap |
|
Project Gyre Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.81) | (0.85) | |
| Return On Capital Employed | (0.70) | (0.73) | |
| Return On Assets | (0.80) | (0.84) | |
| Return On Equity | 5.87 | 6.17 |
When accessing Gyre Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Gyre Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Gyre Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Gyre Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gyre Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Gyre Therapeutics' management manipulating its earnings.
Evaluate Gyre Therapeutics' management efficiency
Gyre Therapeutics has return on total asset (ROA) of 0.1018 % which means that it generated a profit of $0.1018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8274) %, meaning that it created substantial loss on money invested by shareholders. Gyre Therapeutics' management efficiency ratios could be used to measure how well Gyre Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 6.17, whereas Return On Tangible Assets are forecasted to decline to (0.85). At present, Gyre Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 88 M, whereas Intangible Assets are forecasted to decline to about 194.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.19 | 1.25 | |
| Tangible Book Value Per Share | 1.17 | 1.22 | |
| Enterprise Value Over EBITDA | 75.42 | 71.65 | |
| Price Book Value Ratio | (98.95) | (94.00) | |
| Enterprise Value Multiple | 75.42 | 71.65 | |
| Price Fair Value | (98.95) | (94.00) | |
| Enterprise Value | 1.5 B | 2.2 B |
The strategic initiatives led by Gyre Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 9.0032 | Revenue 111.6 M | Quarterly Revenue Growth (0.14) | Revenue Per Share 1.464 | Return On Equity (0.83) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gyre Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gyre Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gyre Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Epstein David M. over three months ago Acquisition by Epstein David M. of 52000 shares of Gyre Therapeutics at 9.98 subject to Rule 16b-3 | ||
Epstein David M. over three months ago Insider Trading | ||
Nussbaum Rodney L over three months ago Acquisition by Nussbaum Rodney L of 1866 shares of Gyre Therapeutics at 17.86 subject to Rule 16b-3 | ||
Usman Nassim over six months ago Disposition of 100 shares by Usman Nassim of Gyre Therapeutics at 15.63 subject to Rule 16b-3 | ||
Williams Eddie over six months ago Gyre Therapeutics exotic insider transaction detected | ||
Wu Charles C over a year ago Acquisition by Wu Charles C of 170417 shares of Gyre Therapeutics subject to Rule 16b-3 | ||
Usman Nassim over a year ago Acquisition by Usman Nassim of 341652 shares of Gyre Therapeutics subject to Rule 16b-3 |
Gyre Therapeutics Corporate Filings
| 14th of November 2024 Other Reports | ViewVerify | |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 6th of September 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
F4 | 16th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Gyre Therapeutics Earnings per Share Projection vs Actual
When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.04) | Revenue Per Share 1.464 | Quarterly Revenue Growth (0.14) | Return On Assets 0.1018 |
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.